TABLE 2.
Pharmacokinetic parameters for oral and intraperitoneal PMPA at 10 mg/kg in male beagle dogsa
| Route of administration | Analysis method | Cmax (μg/ml) | Tmax (h) | AUC (μg · h/ml) | Terminal t1/2 (h) | Bioavailability (%) | % Dose recovered in urine at 48 h |
|---|---|---|---|---|---|---|---|
| Oral (n = 5) | NC | 1.29 (0.54) | 1.00 (0.00) | 6.38 (2.08) | 7.31 (3.04) | 17.1 (1.88) | 20.5 (5.13) |
| C | 1.09 (0.43) | 1.06 (0.15) | 6.78 (2.49) | 9.49 (3.56) | 18.5 (6.79) | ||
| Intraperitoneal (n = 3) | NC | 9.69 (2.11) | 0.42 (0.14) | 19.3 (3.58) | 7.23 (1.35) | 73.5 (10.5) | 62.5 (14.5) |
| C | 9.71 (2.43) | 0.38 (0.21) | 17.7 (4.74) | 4.97 (3.56) | 67.4 (15.4) |
a
Values are means (SDs). Bioavailability was calculated by using data obtained after the intravenous administration of PMPA to the same animals. Abbreviations: NC, noncompartmental analysis; C, two-compartment model; Tmax, time to Cmax; t1/2, half-life.